Restorative Therapies, Inc., Receives FDA Clearance for RT300 En...(t enhancements to the RT300 system make ...),Health

Date:9/7/2009

t enhancements to the RT300 system make it a truly flexible FES cycling system" says Andrew Barriskill, CEO of Restorative Therapies. "Therapists can select any of the major muscle groups for stimulation while their patient works with the ergometer. All of the therapy data continues to be logged to the RT300's Internet database"

For further details please contact Judy Kline, 800 609-9166.

About Restorative Therapies, Inc.
Restorative Therapies, is a privately-held company headquartered in Baltimore, Md., whose mission is to help people with neurological impairment achieve their full recovery potential. Restorative Therapies is one of the first companies to target activity-based therapy and FES as a treatment for immobility associated with paralysis such as stroke, cerebral palsy, multiple sclerosis and spinal cord injury.

Restorative Therapies is now also marketing the RT300 directly into Australia and Canada. Distributors have been appointed in several other key markets.

About Prof. Susan Harkema
Susan Harkema, PhD, is the Associate Professor and Rehabilitation Research Director of the Kentucky Spinal Cord Injury Research Center at the Department of Neurological Surgery, University of Louisville.

Prof. Harkema's primary research aim is to understand neural mechanisms responsible for human locomotion and the level of plasticity after neurologic injury. Prof. Harkema's studies emphasize the importance of basic neural principles of locomotion that are applicable to all animals. The results of her studies contribute to the knowledge about the fundamental mechanisms of control of human locomotion and may provide strategies than can be used by physical therapists for the rehabilitation of walking for patients after neurologic injury.

# # #

Read the full
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine news :

1. Nurses working overnight support the need for a restorative nap during the night shift
2. Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
3. Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management
4. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
5. Growth in the Parkinsons Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
6. Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
7. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
8. e-Telmed, Inc., the Leading Telehealth Solution Provider, Signs Exclusive Agreement with Synergistic Healthcare
9. The Nation's Leading Provider of Medical Transcription Services to Physician Practices, MxSecure, Inc., Named to Inc. 5000 Fastest Growing Private Companies in America
10. Brookhaven Lab and Hybridyne Imaging Technologies Inc., win R&D 100 award
11. "Aprima Medical Software, Inc.," Unveiled by iMedica; Premier EHR / PM Company Adopts New Name